NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Apr 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZYPREXA ZYDIS (olanzapine) by Aurobindo Pharma is olanzapine, in the listed indications is unclear. First approved in 2000.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYPREXA ZYDIS is an orally disintegrating tablet formulation of olanzapine, an atypical antipsychotic approved in 2000. It works primarily through dopamine and serotonin 5-HT2 antagonism to treat schizophrenia and related psychiatric conditions. The rapid-dissolve formulation addresses adherence challenges in patient populations requiring antipsychotic therapy.
$3MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with moderate competitive pressure (30), indicating a defending/transition posture rather than growth-focused commercial expansion.
Mechanism of Action
olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.
Pharmacologic Class:
Atypical Antipsychotic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
Started Nov 2024
654 enrolled
Schizophrenia
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
Started Jul 2024
66 enrolled
Advanced Malignant Solid NeoplasmAdvanced Biliary Tract CarcinomaAdvanced Esophageal Carcinoma+7 more
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
Started Mar 2024
106 enrolled
Schizophrenia, Schizoaffective Disorder
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
Started Mar 2024
153 enrolled
Schizophrenia
A Study of Olanzapine After Intranasal and Intramuscular Administration
Started Oct 2023
24 enrolled
Healthy
Worked on ZYPREXA ZYDIS at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.